Last reviewed · How we verify
Oral Prednisone 10mg
At a glance
| Generic name | Oral Prednisone 10mg |
|---|---|
| Sponsor | SkyePharma AG |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- DIARRHOEA
- ANAEMIA
- CONSTIPATION
- OEDEMA PERIPHERAL
- NEUTROPENIA
- FATIGUE
- BACK PAIN
- NAUSEA
- INSOMNIA
- ASTHENIA
- COUGH
- DECREASED APPETITE
Key clinical trials
- Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis (PHASE3)
- Tolerance by Engaging Antigen During Cellular Homeostasis (PHASE1)
- Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD) (PHASE2)
- Upadacitinib Combined With Corticosteroids vs Corticosteroid Monotherapy Induction for Inpatients and Outpatients With Acute Severe Ulcerative Colitis (PHASE4)
- Safety and Efficacy of Tocilizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (PHASE2, PHASE3)
- Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas (PHASE1, PHASE2)
- Induction Therapy for Lupus Nephritis With no Added Oral Steroids: A Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMF (PHASE3)
- Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral Prednisone 10mg CI brief — competitive landscape report
- Oral Prednisone 10mg updates RSS · CI watch RSS
- SkyePharma AG portfolio CI